SCHEMBL1073247

SCHEMBL1073247

C=C(C)CC(CC(=C)C)(C(=O)OCC)C(=O)OCC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
ALDH1A1 P00352 4/20 0.42
LMNA P02545 2/20 0.42
HSD17B10 Q99714 1/20 0.42
PKM P14618 3/20 0.41
KDM4E B2RXH2 1/20 0.41
THRB P10828 2/20 0.40
HTT P42858 1/20 0.39
TSHR P16473 2/20 0.36
CYP4F2 P78329 2/20 0.36
CYP4A11 Q02928 2/20 0.36
MAPT P10636 1/20 0.36
ATM Q13315 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
ALOX15 P16050 1/20 0.36
MGAM O43451 1/20 0.36
GAA P10253 1/20 0.36
SI P14410 1/20 0.36
MGAM2 Q2M2H8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11254716 0.92 MEN1 (0.43) MEN1KMT2AALDH1A1LMNAHSD17B10
SCHEMBL4740313 0.92 MEN1 (0.43) MEN1KMT2AALDH1A1LMNAHSD17B10
SCHEMBL12215808 0.88 MEN1 (0.44) MEN1KMT2AALDH1A1LMNAHSD17B10
SCHEMBL526722 0.85 MEN1 (0.39) MEN1KMT2AALDH1A1LMNAHSD17B10
SCHEMBL25209687 0.84 MEN1 (0.53) MEN1KMT2AALDH1A1LMNAHSD17B10
SCHEMBL28481211 0.84 MEN1 (0.41) MEN1KMT2AALDH1A1LMNAHSD17B10
SCHEMBL4740322 0.82 MEN1 (0.37) MEN1KMT2AALDH1A1LMNAHSD17B10
SCHEMBL15624149 0.82 MEN1 (0.40) MEN1KMT2AALDH1A1LMNAHSD17B10
SCHEMBL21192369 0.81 MEN1 (0.33) MEN1KMT2APKMKDM4EMAPT
SCHEMBL9785125 0.81 MMP8 (0.44) MEN1KMT2AALDH1A1LMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220219155-A1 Compositions And Methods For Visible-Light-Controlled Ruthenium-Catalyzed Olefin Metathesis THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2022-07-14 US disclosed
US-11331656-B2 Compositions and methods for visible-light-controlled ruthenium-catalyzed olefin metathesis THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2022-05-17 US disclosed
US-20210237045-A1 USE OF N-CHELATING RUTHENIUM COMPLEXES IN THE METATHESIS REACTION APEIRON SYNTHESIS S.A. (PL) 2021-08-05 US disclosed
US-10828628-B2 Homogeneous catalysts that are recoverable by host-guest interactions FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2020-11-10 US disclosed
US-20190344255-A1 Homogeneous Catalysts That Are Recoverable By Host Guest Interactions FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. 2019-11-14 US disclosed
EP-3068768-B1 ANTIDIABETIC TRICYCLIC COMPOUNDS MERCK SHARP & DOHME (US) 2019-07-31 EP disclosed
EP-3068768-B1 ANTIDIABETIC TRICYCLIC COMPOUNDS MERCK SHARP & DOHME (US) 2019-07-31 EP disclosed
US-10357763-B2 Homogeneous catalysts that are recoverable by host guest interactions FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2019-07-23 US disclosed
US-20180065914-A1 RUTHENIUM POLYMERISATION CATALYSTS UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) 2018-03-08 US disclosed
US-20180065914-A1 RUTHENIUM POLYMERISATION CATALYSTS UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) 2018-03-08 US disclosed
WO-2011059803-A2 RUTHENIUM-ALKYLIDENES CONTAINING ACYCLIC DIAMINOCARBENES FOR OBTAINING LOW E/Z RATIOS IN CROSS METATHESIS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2011-05-19 WO disclosed
EP-2276745-A1 RUTHENIUM OLEFIN METATHESIS CATALYSTS BEARING N-HETEROCYCLIC CARBENE LIGANDS WITH SUBSTITUTED BACKBONE Materia, Inc. (US) 2011-01-26 EP disclosed
WO-2009126831-A1 RUTHENIUM OLEFIN METATHESIS CATALYSTS BEARING N-HETEROCYCLIC CARBENE LIGANDS WITH SUBSTITUTED BACKBONE MATERIA, INC. (US) 2009-10-15 WO disclosed
US-20070282148-A1 Organometallic ruthenium complexes and related methods for the preparation of tetra-substituted and other hindered olefins CALIFORNIA INSTITUTE OF TECHNOLOGY 2007-12-06 US disclosed
US-20070282148-A1 Organometallic ruthenium complexes and related methods for the preparation of tetra-substituted and other hindered olefins CALIFORNIA INSTITUTE OF TECHNOLOGY 2007-12-06 US disclosed
WO-2007075427-A1 ORGANOMETALLIC RUTHENIUM COMPLEXES AND RELATED METHODS FOR THE PREPARATION OF TETRA-SUBSTITUTED AND OTHER HINDERED OLEFINS MATERIA, INC. (US) 2007-07-05 WO disclosed
EP-1743899-A1 Metal complexes for use in metathesis, atom transfer radical reactions, addition polymerisation and vinylation reactions, methods and intermediates for making them Universiteit Gent (BE) 2007-01-17 EP disclosed
EP-1468004-B1 METAL COMPLEXES FOR USE IN METATHESIS UNIV GENT (BE) 2006-12-20 EP disclosed
US-6921736-B1 Simply assembled and recyclable polymer-supported olefin metathesis catalysts UNIVERSITY OF NEW ORLEANS RESEARCH AND TECHNOLOGY FOUNDATION, INC. (US) 2005-07-26 US disclosed
EP-1329455-A1 Metal carbene complexes, methods and intermediates for making them and their use in metathesis reactions UNIVERSITEIT GENT (BE) 2003-07-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190344255-A1 Homogeneous Catalysts That Are Recoverable By Host Guest Interactions BLM, INTS9, INF2 MEN1 482/4885KMT2A 2993/4885ALDH1A1 2397/4885
US-20210237045-A1 USE OF N-CHELATING RUTHENIUM COMPLEXES IN THE METATHESIS REACTION CYC1, AP1M1, HNMT MEN1 1082/4885KMT2A 4223/4885ALDH1A1 1856/4885
US-20070282148-A1 Organometallic ruthenium complexes and related methods for the preparation of tetra-substituted and other hindered olefins ORC3, OXER1, CBR3 MEN1 1476/4885KMT2A 2953/4885ALDH1A1 2951/4885
US-11331656-B2 Compositions and methods for visible-light-controlled ruthenium-catalyzed olefin metathesis PPOX, CYBA, CYBB MEN1 1935/4885KMT2A 3381/4885ALDH1A1 1395/4885
US-10357763-B2 Homogeneous catalysts that are recoverable by host guest interactions BLM, INTS9, INF2 MEN1 482/4885KMT2A 2993/4885ALDH1A1 2397/4885
US-20180065914-A1 RUTHENIUM POLYMERISATION CATALYSTS RRP12, PCBP1, PARG MEN1 796/4885KMT2A 3683/4885ALDH1A1 4132/4885
US-10828628-B2 Homogeneous catalysts that are recoverable by host-guest interactions BLM, INTS9, SOD1 MEN1 445/4885KMT2A 2985/4885ALDH1A1 2229/4885
US-20220219155-A1 Compositions And Methods For Visible-Light-Controlled Ruthenium-Catalyzed Olefin Metathesis PPOX, CYBA, CYBB MEN1 1935/4885KMT2A 3381/4885ALDH1A1 1395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.